

**ANNEX I**

**SUMMARY OF PRODUCT CHARACTERISTICS**

## **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Vectra Felis 423 mg/42.3 mg spot-on solution for cats

## **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

### **Active substances:**

Each 0.9 ml spot-on applicator delivers:

Dinotefuran..... 423 mg

Pyriproxyfen..... 42.3 mg

For the full list of excipients, see section 6.1.

## **3. PHARMACEUTICAL FORM**

Spot-on solution.

Colourless to pale yellow solution.

## **4. CLINICAL PARTICULARS**

### **4.1 Target species**

Cats.

### **4.2 Indications for use, specifying the target species**

Treatment and prevention of flea infestations (*Ctenocephalides felis*) on cats.

One application prevents flea infestation for one month. It also prevents the multiplication of fleas by inhibiting flea emergence in the environment of the cat for 3 months.

### **4.3 Contraindications**

Do not use in cats or kittens weighing less than 0.6 kg.

Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

### **4.4 Special warnings for each target species**

All cats within the household should be treated. Dogs in the household should only be treated with a veterinary medicinal product authorised for use in that species.

Fleas can infest the cat's basket, bedding and regular resting areas such as carpets and soft furnishings. In case of massive flea infestation and at the beginning of the control measures, these areas should be treated with a suitable insecticide and then vacuumed regularly.

The impact of shampooing on the efficacy of the veterinary medicinal product has not been evaluated.

In case of suspicion of dermatitis (itch and skin irritation), seek for veterinary advice.

## 4.5 Special precautions for use

### Special precautions for use in animals

The safety of the product has not been established in cats younger than 7 weeks or weighing less than 0.6 kg (see section 4.3).

After accidental ingestion of the product, transient reactions such as salivation, abnormal faeces and emesis may occur, however these should resolve without treatment within 4 hours.

Care should be taken to apply the dose to an area where the animal cannot lick it off (see section 4.9), and to ensure that animals do not groom each other immediately following treatment.

Care should be taken to ensure that the contents of the spot-on applicator, or the applied dose, do not come into contact with the eyes of the cat to be treated and/or any other animals.

No studies have been performed in sick or convalescent cats, therefore use in these cats should be based on the benefit-risk assessment of a veterinarian.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals

People with known hypersensitivity to dinotefuran, pyriproxyfen or dimethyl sulfoxide should avoid contact with this veterinary medicinal product.

The veterinary medicinal product is irritating to the eyes and skin.

To avoid adverse reactions:

- Wash hands thoroughly and immediately after use.
- Avoid contact with the skin, eyes or mouth.
- In case of accidental spillage onto skin, wash off immediately with soap and water.
- If the veterinary medicinal product accidentally gets into the eyes, they should be rinsed with water immediately, with the eyelids open, and for a sufficient length of time.
- Treated animals must not be handled for at least eight hours after application of the product. It is therefore recommended to treat the animal in the evening.
- Treated animals should not be allowed to sleep with their owners, especially children, on the day of treatment.
- Used applicators should be disposed of immediately and not left within the sight or reach of children.

If skin or if eye irritation persists, or in case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

## 4.6 Adverse reactions (frequency and seriousness)

Slight scales, transient erythema and alopecia can be observed in rare cases, which usually disappear spontaneously without treatment.

Transient neurological signs such as muscle tremors or lethargy may occur very rarely and in particular after application site licking.

Transient cosmetic effects such as wet hair and a white dry residue may occur at the application site very rarely and may persist up to 7 days; however, these effects are usually not noticeable after 48 hours. These changes do not affect the safety or the efficacy of the veterinary medicinal product. Other application site disorders such as erythema, pruritus, lesions and inflammation may occur very rarely.

Hyperactivity and tachypnoea may occur very rarely.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

#### **4.7 Use during pregnancy, lactation or lay**

The safety of the veterinary medicinal product has not been established during pregnancy and lactation in adult female cats.

Use only accordingly to the benefit/risk assessment by the responsible veterinarian.

Laboratory studies with each of the components, dinotefuran or pyriproxyfen, in rats and rabbits have not produced any evidence of maternotoxic, teratogenic or foetotoxic effects.

In rats, dinotefuran has been shown to cross the blood-milk barrier and is excreted in the milk.

#### **4.8 Interaction with other medicinal products and other forms of interaction**

None known.

#### **4.9 Amounts to be administered and administration route**

##### Dosage:

The minimum recommended dose is 42.3 mg dinotefuran/kg bodyweight and 4.23 mg pyriproxyfen/kg bodyweight.

The treatment dose range is 42.3 to 705 mg dinotefuran/kg bodyweight (bw) and 4.23 to 70.5 mg pyriproxyfen/kg bodyweight (bw) for cats of 0.6 kg to 10 kg bodyweight.

##### Method and route of administration:

Spot-on use.

Care should be taken to apply the veterinary medicinal product only onto intact (undamaged) cat's skin.

##### Treatment schedule:

Following a single administration, the veterinary medicinal product will prevent flea infestation for one month and prevent further flea multiplication by inhibiting flea emergence in the environment of the cat for 3 months. The need to re-treat cats which are likely to be re-infested, and the time interval between such treatments, should be based on an assessment by a veterinarian.

##### How to apply:

Remove the spot-on applicator from the pack.

**Step 1:** Hold the applicator upright, placing fingers below the larger disk as shown.



**Step 2:** With the other hand, press downwards on the smaller disk until the 2 disks meet evenly. This will pierce the seal.



**Step 3:** The cat should be standing or in a comfortable position for easy application. At the base of cat's head, part the hair until the skin is visible. Apply the veterinary medicinal product slowly with the tip of the applicator on the skin. Avoid superficial application to the cat's hair.



#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

No clinically important adverse reactions were observed in healthy kittens aged 7 weeks or more, topically treated 7 times at 2 week intervals and with up to 4 times the highest recommended dose except transient oedema or dry skin at the application site.

#### **4.11 Withdrawal period(s)**

Not applicable.

### **5. PHARMACOLOGICAL PROPERTIES**

Pharmacotherapeutic group: Antiparasitic products, insecticides and repellents, other ectoparasiticides for topical use.

ATCvet code: QP53AX73.

#### **5.1 Pharmacodynamic properties**

Dinotefuran is an insecticide. Its structure is derived from the neurotransmitter acetylcholine and it acts on nicotinic acetylcholine receptors of the insect nerve synapse. Once bound to these receptors, the full agonist action of repeated excitatory impulses kills the insect. Insects do not have to ingest dinotefuran, it kills by contact. Dinotefuran has a low affinity for mammalian acetylcholine receptor sites. Fleas are killed by dinotefuran within 2 hours after treatment or infestation.

Pyriproxyfen is a photostable insect growth regulator (IGR). It acts through contact, by mimicking the juvenile hormone which regulates the moulting of insects from one life stage to the next. Pyriproxyfen stops the flea life cycle by both inducing premature oviposition and also suppressing yolk deposition in flea eggs, leading to the production of infertile eggs. Pyriproxyfen also blocks the development of juvenile stages (larvae and early (pharate) pupae) into adult emergence. This prevents infestation within the environment of the treated animal.

## **5.2 Pharmacokinetic particulars**

Following topical application, the two actives rapidly distribute over the body surface of the animal within the first day and were still measurable in different zones of the hair coat one month after treatment.

Dinotefuran and pyriproxyfen are partially absorbed by the cat skin (30% and 12% respectively), but this systemic absorption is not relevant for the clinical efficacy of the product.

In laboratory species, after intra-peritoneal administration, dinotefuran is rapidly eliminated as the unchanged parent molecule mainly via the urine. After oral administration, pyriproxyfen is rapidly metabolized, principally by hydroxylation, and eliminated mainly in the faeces, and to a lesser extent in the urine.

## **Environmental properties**

Vectra Felis should not enter water courses as this may be dangerous for fish and other aquatic organisms. Do not contaminate ponds, waterways or ditches with the veterinary medicinal product or with used containers.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Dimethyl sulfoxide

### **6.2 Major incompatibilities**

None known.

### **6.3 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

Shelf life after first opening the immediate packaging: use immediately.

### **6.4 Special precautions for storage**

This veterinary medicinal product does not require any special storage conditions.

### **6.5 Nature and composition of immediate packaging**

Spot-on applicator made of a multilayered complex of aluminium and polyethylene (PE) with a head made of HDPE, top-sealed with a liner complex (aluminium/polyester/sealable PE layer).

Pack sizes:

Cardboard box of 1, 3, 4, 6, 12 or 24 spot-on applicator(s).

Not all pack sizes may be marketed.

### **6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Vectra Felis should not enter water courses as this may be dangerous for fish and other aquatic organisms. Do not contaminate ponds, waterways or ditches with the veterinary medicinal product or with used containers.

**7. MARKETING AUTHORISATION HOLDER**

Ceva Santé Animale  
10, av. de La Ballastière  
33500 Libourne  
FRANCE

**8. MARKETING AUTHORISATION NUMBER(S)**

EU/2/14/165/001–004  
EU/2/14/165/006–007

**9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 06/06/2014  
Date of last renewal: 08/02/2019

**10. DATE OF REVISION OF THE TEXT**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu/>).

**PROHIBITION OF SALE, SUPPLY AND/OR USE**

Not applicable.

## **ANNEX II**

- A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**
- C. STATEMENT OF THE MRLs**
- D. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**



**A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**

Ceva Santé Animale  
10, av. de La Ballastière  
33500 Libourne  
France

AB7 SANTE  
Chemin des Monges  
31450 Deyme  
France

**B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**

Veterinary medicinal product not subject to prescription.

**C. STATEMENT OF THE MRLs**

Not applicable.

**D. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

Specific pharmacovigilance requirements:

The periodic safety update report (PSUR) cycle should be restarted for submission of 6 monthly reports (covering all authorised presentations of the product) for the next two years, followed by yearly reports for the subsequent two years and thereafter at 3 yearly intervals.

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

Cardboard box of 1, 3, 4, 6, 12 and 24 spot-on applicators

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Vectra Felis 423 mg/42.3 mg spot-on solution for cats  
dinotefuran/pyriproxyfen

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each 0.9 ml spot-on applicator contains dinotefuran 423 mg and pyriproxyfen 42.3 mg.

**3. PHARMACEUTICAL FORM**

Spot-on solution

**4. PACKAGE SIZE**

1 spot-on applicator  
3 spot-on applicators  
4 spot-on applicators  
6 spot-on applicators  
12 spot-on applicators  
24 spot-on applicators

**5. TARGET SPECIES**

Cats.

**6. INDICATION(S)**

Treatment and prevention of infestations with fleas for 1 month.  
Prevention of flea multiplication for 3 months.



Flea

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

See package leaflet for instructions for use.  
Spot-on use for external application to the skin.

**8. WITHDRAWAL PERIOD(S)****9. SPECIAL WARNING(S), IF NECESSARY**

Avoid contact of the product with your skin, eyes or mouth.  
Treated animals must not be handled for at least 8 hours after application of the product.  
Read the package leaflet before use.

**10. EXPIRY DATE**

Once opened, use immediately.  
EXP {month/year}

**11. SPECIAL STORAGE CONDITIONS****12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable**

For animal treatment only.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Ceva Santé Animale  
10, av. de La Ballastière  
33500 Libourne  
FRANCE

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/14/165/001 (1 spot-on applicator)  
EU/2/14/165/002 (3 spot-on applicators)  
EU/2/14/165/006 (4 spot-on applicators)  
EU/2/14/165/003 (6 spot-on applicators)  
EU/2/14/165/004 (12 spot-on applicators)  
EU/2/14/165/007 (24 spot-on applicators)

<b>17. MANUFACTURER'S BATCH NUMBER</b>
--

Lot:

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS****Spot-on applicator****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Vectra Felis spot-on

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

Each 0.9 ml spot-on applicator contains dinotefuran 423 mg and pyriproxyfen 42.3 mg.

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES****4. ROUTE(S) OF ADMINISTRATION**

Spot-on use

**5. WITHDRAWAL PERIOD(S)****6. BATCH NUMBER**

Lot {number}

**7. EXPIRY DATE**

EXP {month/year}

**8. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

## **B. PACKAGE LEAFLET**



**PACKAGE LEAFLET:**  
**Vectra Felis 423 mg/42.3 mg spot-on solution for cats**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder:

Ceva Santé Animale, 10, av. de La Ballastière, 33500 Libourne, France

Manufacturer responsible for batch release:

Ceva Santé Animale, 10, av. de La Ballastière, 33500 Libourne, France  
AB7 SANTE, Chemin des Monges, 31450 Deyme, France

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Vectra Felis 423 mg/42.3 mg spot-on solution for cats  
dinotefuran/pyriproxyfen

**3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS**

Each 0.9 ml spot-on applicator delivers: 423 mg dinotefuran and 42.3 mg pyriproxyfen.  
Colourless to pale yellow spot-on solution.

**4. INDICATION(S)**

This veterinary medicine kills fleas (*Ctenocephalides felis*) on infested cats and prevents further infestations for one month. It also prevents the multiplication of fleas, by inhibiting immature flea emergence in the cat's environment, for 3 months.

**5. CONTRAINDICATIONS**

Do not use in cats or kittens weighing less than 0.6 kg.  
Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

**6. ADVERSE REACTIONS**

Slight scales, transient erythema and alopecia can be observed in rare cases, which usually disappear spontaneously without treatment.

Transient neurological signs such as muscle tremors or lethargy may occur very rarely and in particular after application site licking.

Transient cosmetic effects such as wet hair and a white dry residue may occur at the application site very rarely and may persist up to 7 days; however, these effects are usually not noticeable after 48 hours. These changes do not affect the safety or the efficacy of the veterinary medicinal product. Other application site disorders such as erythema, pruritus, lesions and inflammation may occur very rarely.

Hyperactivity and tachypnoea may occur very rarely.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)

- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

## **7. TARGET SPECIES**

Cats.

## **8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

### Method and route of administration:

Spot-on use.

Care should be taken to apply the veterinary medicine only onto intact (undamaged) cat's skin.

### Dosage:

Use one spot-on applicator for one administration on one cat only.

The use in cats younger than 7 weeks or weighing less than 0.6 kg is not recommended.

(The minimum recommended dose is 42.3 mg dinotefuran/kg bodyweight and 4.23 mg pyriproxyfen/kg bodyweight. The treatment dose range is 42.3 to 705 mg dinotefuran/kg bodyweight and 4.23 to 70.5 mg pyriproxyfen/kg bodyweight for cats which weigh between 0.6 kg and 10 kg).

### Treatment schedule:

Following a single administration, the veterinary medicinal product will prevent flea infestation for one month and further flea multiplication by inhibiting flea emergence in the environment of the cat for 3 months. The need to re-treat cats which are likely to be re-infested, and the time interval between such treatments, should be based on an assessment by a veterinarian.

## **9. ADVICE ON CORRECT ADMINISTRATION**

### How to apply:

Remove the spot-on applicator from the pack.

**Step 1:** Hold the applicator upright, placing fingers below the larger disk as shown.



**Step 2:** With the other hand, press downwards on the smaller disk until the 2 disks meet evenly. This will pierce the seal.



**Step 3:** The cat should be standing or in a comfortable position for easy application. At the base of cat's head, part the hair until the skin is visible. Apply the veterinary medicinal product slowly with the tip of the applicator on the skin. Avoid superficial application to the cat's hair.



#### **10. WITHDRAWAL PERIOD(S)**

Not applicable.

#### **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and spot-on applicator after "EXP". The expiry date refers to the last day of that month.

#### **12. SPECIAL WARNING(S)**

##### Special warnings for each target species:

All cats within the household should be treated. Dogs in the household should only be treated with a veterinary medicinal product authorised for use in that species.

Fleas can infest the cat's basket, bedding and regular resting areas such as carpets and soft furnishings. In case of massive flea infestation and at the beginning of the control measures, these areas should be treated with a suitable insecticide and then vacuumed regularly.

The impact of shampooing on the efficacy of the veterinary medicinal product has not been evaluated. In case of suspicion of dermatitis (itch and skin irritation), seek for veterinary advice.

##### Special precautions for use in animals:

For external use only.

Apply only to the skin surface. Do not administer orally or via any other route.

The safety of this veterinary medicine has not been established in cats younger than 7 weeks of age or weighing less than 0.6 kg (see section "Contraindications").

After accidental ingestion of the product, transient reactions such as salivation, abnormal faeces and emesis may occur, however these should resolve without treatment within 4 hours.

Care should be taken to apply the dose to an area where the animal cannot lick it off (as described in section "Advice on correct administration"), and to ensure that animals do not groom each other immediately following treatment.

Care should be taken to ensure that the contents of the spot-on applicator, or the applied dose, do not come into contact with the eyes of the cat to be treated and/or any other animals.

No studies have been performed in sick or convalescent cats, therefore use in these cats should be based on the benefit-risk assessment of a veterinarian.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

People with known hypersensitivity to dinotefuran, pyriproxyfen or dimethyl sulfoxide should avoid contact with this veterinary medicinal product.

The veterinary medicinal product is irritating to the eyes and skin.

To avoid adverse reactions:

- Wash hands thoroughly and immediately after use.
- Avoid contact with the skin, eyes or mouth.
- In case of accidental spillage onto skin, wash off immediately with soap and water.
- If the veterinary medicinal product accidentally gets into the eyes, they should be rinsed with water immediately, with the eyelids open, and for a sufficient length of time.
- Treated animals must not be handled for at least eight hours after application of the product. It is therefore recommended to treat the animal in the evening.
- Treated animals should not be allowed to sleep with their owners, especially children, on the day of treatment.
- Used applicators should be disposed of immediately and not left within the sight or reach of children.

If skin or if eye irritation persists, or in case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation in adult female cats. Use only accordingly to the benefit/risk assessment by the responsible veterinarian.

Laboratory studies with the active substances, dinotefuran or pyriproxyfen, in rats and rabbits have not produced any evidence of birth defects or other harmful effects in the developing embryo or foetus (teratogenic, foetotoxic) or harmful effects for the mother (maternotoxic effects).

In rats, dinotefuran has been shown to cross the blood-milk barrier and is excreted in the milk.

Interaction with other medicinal products and other forms of interaction:

None known.

Overdose (symptoms, emergency procedures, antidotes):

No important adverse reactions were observed in healthy kittens aged 7 weeks or more, topically treated 7 times at 2 week intervals and with up to 4 times the highest recommended dose except transient oedema or dry skin at the application site.

Incompatibilities:

None known.

**13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Vectra Felis should not enter water courses as this may be dangerous for fish and other aquatic organisms. Do not contaminate ponds, waterways or ditches with the veterinary medicinal product or with used containers.

Medicines should not be disposed of via wastewater or household waste.

Unused product or waste material derived from the product should be disposed of following local regulation. These measures should help to protect the environment.

#### **14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu/>).

#### **15. OTHER INFORMATION**

Pack sizes:

Cardboard box of 1, 3, 4, 6, 12 or 24 spot-on applicator(s).

Not all pack sizes may be marketed.

Mechanisms of action:

The two active ingredients in the product spread over the body surface of the cat within the first day after application. The actives act directly on the cat's coat without any need to infiltrate the blood flow. The parasite comes in contact with the treated cat and is then killed.

Dinotefuran kills insects by targeting their nervous system.

Pyriproxyfen targets the immature stages of insects (eggs, larvae, pupae) by disruption of their reproduction and development. Flea eggs, larvae and pupae are present in the environment.

The veterinary medicinal product kills fleas within 2 hours after application of the product or 2 hours after infestation of the treated animal.